Managing Ocular Toxicity, Stomatitis, and ILD With Dato-DXd

The panel reviews the distinct adverse event profile associated with datopotamab deruxtecan, moving from least to most common. Panelists discuss interstitial lung disease, noting its relatively low incidence in the trial setting while emphasizing the value of baseline imaging, symptom-directed monitoring, and prompt management. The conversation then turns to stomatitis and oral mucositis, where proactive prophylaxis with steroid mouthwash, good oral hygiene, and oral cryotherapy can reduce both incidence and severity. Panelists also address ocular toxicity, reviewing recommendations for baseline and periodic eye exams, the practical workflow of partnering with optometry or ophthalmology, and the role of preservative-free lubricating drops. A practical, encouraging theme runs throughout: these are largely early-grade, surface-level events that should not become a barrier to effective treatment, and continued adherence to prophylaxis matters even when patients feel well. Viewers gain concrete, real-world guidance for keeping patients on therapy comfortably.